(Q51191468)

English

Hepatitis B e antigen predicts delayed reduction of HBV DNA without viral breakthrough with adefovir dipivoxil and lamivudine: a 5-year study of patients with hepatitis B with lamivudine resistance.

scientific article published in October 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/22930504

Hepatitis B e antigen predicts delayed reduction of HBV DNA without viral breakthrough with adefovir dipivoxil and lamivudine: a 5-year study of patients with hepatitis B with lamivudine resistance. (English)

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/22930504

1 reference

based on heuristic

inferred from title

author name string

Fusao Ikeda

1

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/22930504

Nobuyuki Baba

2

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/22930504

Koichi Takaguchi

3

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/22930504

Junichi Kubota

4

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/22930504

Kenji Miyoshi

5

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/22930504

Shin-Ichi Fujioka

6

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/22930504

Yuki Moritou

7

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/22930504

Yasuto Takeuchi

8

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/22930504

Tetsuya Yasunaka

9

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/22930504

Yasuhiro Miyake

10

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/22930504

Akinobu Takaki

11

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/22930504

Yoshiaki Iwasaki

12

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/22930504

Haruhiko Kobashi

13

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/22930504

Kazuhide Yamamoto

14

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/22930504

publication date

1 October 2012

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/22930504

Journal of Medical Virology

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/22930504

84

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/22930504

10

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/22930504

1562-1570

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/22930504

Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23371

21 January 2018

Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23371

21 January 2018

Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23371

21 January 2018

Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23371

21 January 2018

Efficacy and resistance of entecavir following 3 years of treatment of Japanese patients with lamivudine-refractory chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23371

21 January 2018

Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23371

21 January 2018

Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23371

21 January 2018

Imaging diagnosis of hepatocellular carcinoma and premalignant/borderline lesions

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23371

21 January 2018

Factors contributing to antiviral effect of adefovir dipivoxil therapy added to ongoing lamivudine treatment in patients with lamivudine-resistant chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23371

21 January 2018

Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23371

21 January 2018

Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23371

21 January 2018

rtL180M mutation of hepatitis B virus is closely associated with frequent virological resistance to adefovir dipivoxil therapy.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23371

21 January 2018

Lamivudine for patients with chronic hepatitis B and advanced liver disease

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23371

21 January 2018

Navigating the maze of hepatitis B treatments

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23371

21 January 2018

Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23371

21 January 2018

Importance of serum concentration of adefovir for Lamivudine-adefovir combination therapy in patients with lamivudine-resistant chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23371

21 January 2018

A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23371

21 January 2018

Radiologic diagnosis of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23371

21 January 2018

Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23371

21 January 2018

A novel variant genotype C of hepatitis B virus identified in isolates from Australian Aborigines: complete genome sequence and phylogenetic relatedness

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23371

21 January 2018

Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23371

21 January 2018

Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23371

21 January 2018

Treatment recommendations for chronic hepatitis B: an evaluation of current guidelines based on a natural history study in the United States

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23371

21 January 2018

Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23371

21 January 2018

Hepatitis B e antigen and the risk of hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23371

21 January 2018

Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23371

21 January 2018

Hepatitis B virus resistance to nucleos(t)ide analogues.

1 reference

https://api.crossref.org/works/10.1002%2FJMV.23371

21 January 2018

Identifiers

10.1002/JMV.23371

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/22930504

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

1 April 2018

http://europepmc.org/abstract/MED/22930504

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51191468&oldid=1696374688"